View our other reports:
1st Quarter Report 2007
(PDF: 195Kb)
2nd Quarter Report 2007
(PDF: 231Kb)
3rd Quarter Report 2007
(PDF: 208Kb)
Annual Report 2006
(PDF: 1.09)
1st Quarter Report 2006
(PDF: 786Kb)
2nd Quarter Report 2006
(PDF: 956Kb)
3rd Quarter Report 2006
(PDF: 787Kb)
Annual Report 2005
(PDF: 3.6Mb)
GSK facts
- GSK dedicated to R&D for 80 years
- Cost of bringing a medicine to market: $800 million (Rs 4.8 billion)
- Average length of time to discover new drug: 10-15 years
- 5 out of every 10,000 compounds investigated reach clinical trial phase and only 1 of those gets approved for patient use.
- GSK has industry's most extensive portfolio of R&D projects for diseases affecting developing countries
GSK Pakistan overview
GSK Pakistan Limited was created on January 1st 2000 through the merger of SmithKline Beecham (Pakistan) and Glaxo Wellcome (Pakistan) and it stands as the largest pharmaceutical company in Pakistan today.
GSK leads the industry in value, volume and prescription market shares. We are proud of our consistency and stability in sales, profits and growth. Some of our key brands include Augmentin, Panadol, Seretide, Betnovate, Zantac and Calpol in medicine and renowned consumer healthcare brands include Horlicks, Aquafresh, Macleans and ENO.